Glycosylated Delta-RBD mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge

Xiaoqing Guan; Abhishek K. Verma; Gang Wang; Juan Shi; Stanley Perlman; Lanying Du

doi:10.1016/j.isci.2023.108033

Back

Glycosylated Delta-RBD mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge

Journal article

Open access

Peer reviewed

Glycosylated Delta-RBD mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge

Xiaoqing Guan, Abhishek K. Verma, Gang Wang, Juan Shi, Stanley Perlman and Lanying Du

iScience, Vol.26(10), 108033

10/2023

DOI: 10.1016/j.isci.2023.108033

PMCID: PMC10563057

PMID: 37822493

Files and links (1)

url

https://doi.org/10.1016/j.isci.2023.108033View

Published (Version of record) Open Access

Abstract

Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site. Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD) mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those induced by intramuscular injection of the same vaccine or Omicron-S subunit vaccine, as well as high mucosal IgA antibody responses. It elicited broadly neutralizing antibodies against the original SARS-CoV-2 strain, Delta and Omicron BA1/BA2 variants, completely protecting transgenic mice from lethal challenge with a Delta variant, including complete absence of weight loss. Of note, intramuscular priming with the Omicron-S protein followed by intranasal boosting with the Delta-RBD protein improved the vaccine’s ability to generate broad-spectrum neutralizing antibodies against recent BA5 and XBB Omicron variants. Overall, this vaccine has potential to prevent SARS-CoV-2 infection of the respiratory mucosa, while the i.m. priming and i.n. boosting vaccination strategy may offer protection against known and emerging SARS-CoV-2 variants.

Details

Title: Subtitle: Glycosylated Delta-RBD mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
Creators: Xiaoqing Guan
Abhishek K. Verma
Gang Wang
Juan Shi
Stanley Perlman
Lanying Du
Resource Type: Journal article
Publication Details: iScience, Vol.26(10), 108033
DOI: 10.1016/j.isci.2023.108033
PMID: 37822493
PMCID: PMC10563057
NLM abbreviation: iScience
ISSN: 2589-0042
eISSN: 2589-0042
Grant note: DOI: 10.13039/100000002, name: National Institutes of Health, award: R01AI137472, R01AI139092, R01AI157975
Language: English
Electronic publication date: 09/2023
Date published: 10/2023
Academic Unit: Microbiology and Immunology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Infectious Disease (Pediatrics)
Record Identifier: 9984472654602771

Metrics

9 Record Views

6 Times Cited - Web of Science